Max Hodak

Max Hodak is the Founder and CEO of Science Corporation, a leader in brain-computer interfaces (BCI) focused on restoring vision, cognition, and mobility to those with debilitating conditions for which there are no treatment options Science’s PRIMA retina implant for patients blinded with late stage macular degeneration (loss of central visual field) has completed pivotal clinical trials with over eighty percent of patients achieving significant visual acuity improvements, making it the first BCI technology to restore functional vision to these patients. PRIMA received U.S. FDA Breakthrough status in 2023 and is currently in the process of gaining both FDA and European approval. Prior to founding Science, Max was president of Neuralink, which he co-founded in 2016. Max began his life-long passion for BCI as a young child and started programming at the age of six. As a freshman at Duke University’s Pratt School of Engineering, studying biomedical engineering, he worked his way into the renowned Nicolelis Lab – one of the best neural engineering labs in the country, typically open only to graduate students – and spent his undergraduate years immersed in BCI research. Since graduating from Duke, his primary research and professional focus has been on neural engineering and the brain.